- BMS-202
-
- $102.00 / 5mg
-
2026-03-13
- CAS:1675203-84-5
- Min. Order:
- Purity: 98.29%
- Supply Ability: 10g
- PD-L1 inhibitor 1
-
- $5.50 / 1KG
-
2020-01-10
- CAS:1675203-84-5
- Min. Order: 1KG
- Purity: 98%min
- Supply Ability: 1kg,10kg,100kg
|
| | PD-L1 inhibitor 1 Basic information |
| Product Name: | PD-L1 inhibitor 1 | | Synonyms: | PD-L1 inhibitor 1;PD1-PDL1 inhibitor 2;N-[2-[[[2-Methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]acetamide;BMS-202;Acetamide, N-[2-[[[2-methoxy-6-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]-3-pyridinyl]methyl]amino]ethyl]-;PD 1 inhibitor 2;PD1 inhibitor 2;PD-1 inhibitor 2 | | CAS: | 1675203-84-5 | | MF: | C25H29N3O3 | | MW: | 419.52 | | EINECS: | | | Product Categories: | | | Mol File: | 1675203-84-5.mol |  |
| | PD-L1 inhibitor 1 Chemical Properties |
| Boiling point | 611.4±55.0 °C(Predicted) | | density | 1.133±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml) | | form | solid | | pka | 16.06±0.46(Predicted) | | color | White | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| | PD-L1 inhibitor 1 Usage And Synthesis |
| Description | The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction plays a dominant role in the suppression of T cell responses, especially in a tumor microenvironment, protecting tumor cells from lysis. PD-1/PD-L1 inhibitor 2 is reported to prevent the interaction of PD-L1 with PD-1 with an IC50 value of 18 nM. | | Uses | BMS-202 is a Novel inhibitor of the PD-1/PD-L1 interaction by inducing PD-L1 dimerization through PD-1 interacting surface. | | in vivo | BMS-202 (20 mg/kg; intraperitoneal injection; daily; for 9 days; NOG-dKO mice) treatment shows a clear antitumor effect compared with the controls, in humanized MHC- dKO NOG mice[2]. | Animal Model: | NOG-dKO mice (8-week-old) injected with SCC-3 cells[2] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection; daily; for 9 days | | Result: | Showed 41% growth inhibitory activity against humanized mouse-transplanted human lymphoma SCC-3 cells.
|
| | References | [1] KRZYSZTOF M ZAK. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).[J]. Oncotarget, 2016: 30323-30335. DOI:10.18632/oncotarget.8730
[2] KATARZYNA GUZIK. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1[J]. Journal of Medicinal Chemistry, 2017, 60 13: 5857-5867. DOI:10.1021/acs.jmedchem.7b00293 |
| | PD-L1 inhibitor 1 Preparation Products And Raw materials |
|